Patients with Coronary Artery Disease Have Lower Levels of Antibody to Heat-Stressed Fibroblast Derived Proteins, versus Normal Subjects. (17th June 2021)
- Record Type:
- Journal Article
- Title:
- Patients with Coronary Artery Disease Have Lower Levels of Antibody to Heat-Stressed Fibroblast Derived Proteins, versus Normal Subjects. (17th June 2021)
- Main Title:
- Patients with Coronary Artery Disease Have Lower Levels of Antibody to Heat-Stressed Fibroblast Derived Proteins, versus Normal Subjects
- Authors:
- Aghamajidi, Azin
Khameneh, Hesam Babaei
Amirjamshidi, Narges
Jalali, Seyed Farzad
Akhavan-Niaki, Haleh
Khafri, Soraya
Mousavi, Seyedeh Narges
Golpour, Monireh
Mehri, Maryam
AmrollahMostafazadeh, - Other Names:
- Imig John D. Academic Editor.
- Abstract:
- Abstract : Cellular stress response plays an important role in the pathophysiology of coronary artery disease (CAD). Inhibition of cellular stress may provide a novel clinical approach regarding the diagnosis and treatment of CAD. Fibroblasts constitute 60-70% of cardiac cells and have a crucial role in cardiovascular function. Hence, the aim of this study was to show a potential therapeutic application of proteins derived from heat-stressed fibroblast in CAD patients. Fibroblasts were isolated from the foreskin and cultured under heat stress conditions. Surprisingly, 1.06% of the cells exhibited a necrotic death pattern. Furthermore, heat-stressed fibroblasts produced higher level of total proteins than control cells. In SDS-PAGE analysis, a 70 kDa protein band was observed in stressed cell culture supernatants which appeared as two acidic spots with close pI in the two-dimensional electrophoresis. To evaluate the immunogenic properties of fibroblast-derived heat shock proteins (HSPs), the serum immunoglobulin-G (IgG) was measured by ELISA in 50 CAD patients and 50 normal subjects who had been diagnosed through angiography. Interestingly, the level of anti-HSP antibody was significantly higher in non-CAD individuals in comparison with the patient's group (p < 0.05 ). The odds ratio for CAD was 5.06 (95 % CI = 2.15 ‐ 11.91 ) in cut-off value of 30 AU/mL of anti-HSP antibody. Moreover, ROC analysis showed that anti-HSP antibodies had a specificity of 74% and a sensitivity ofAbstract : Cellular stress response plays an important role in the pathophysiology of coronary artery disease (CAD). Inhibition of cellular stress may provide a novel clinical approach regarding the diagnosis and treatment of CAD. Fibroblasts constitute 60-70% of cardiac cells and have a crucial role in cardiovascular function. Hence, the aim of this study was to show a potential therapeutic application of proteins derived from heat-stressed fibroblast in CAD patients. Fibroblasts were isolated from the foreskin and cultured under heat stress conditions. Surprisingly, 1.06% of the cells exhibited a necrotic death pattern. Furthermore, heat-stressed fibroblasts produced higher level of total proteins than control cells. In SDS-PAGE analysis, a 70 kDa protein band was observed in stressed cell culture supernatants which appeared as two acidic spots with close pI in the two-dimensional electrophoresis. To evaluate the immunogenic properties of fibroblast-derived heat shock proteins (HSPs), the serum immunoglobulin-G (IgG) was measured by ELISA in 50 CAD patients and 50 normal subjects who had been diagnosed through angiography. Interestingly, the level of anti-HSP antibody was significantly higher in non-CAD individuals in comparison with the patient's group (p < 0.05 ). The odds ratio for CAD was 5.06 (95 % CI = 2.15 ‐ 11.91 ) in cut-off value of 30 AU/mL of anti-HSP antibody. Moreover, ROC analysis showed that anti-HSP antibodies had a specificity of 74% and a sensitivity of 64%, which is almost equal to 66% sensitivity of exercise stress test (EST) as a CAD diagnostic method. These data revealed that fibroblast-derived HSPs are suitable for the diagnosis and management of CAD through antibody production. … (more)
- Is Part Of:
- Cardiovascular therapeutics. Volume 2021(2021)
- Journal:
- Cardiovascular therapeutics
- Issue:
- Volume 2021(2021)
- Issue Display:
- Volume 2021, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 2021
- Issue:
- 2021
- Issue Sort Value:
- 2021-2021-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-06-17
- Subjects:
- Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals
Cardiovascular Agents -- Periodicals
Cardiovascular Diseases -- drug therapy -- Periodicals
Agents cardiovasculaires -- Périodiques
Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques
616.1005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922 ↗
http://www.blackwell-synergy.com/loi/cath ↗
http://www.blackwellpublishing.com/journal.asp?ref=1755-5914&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1155/2021/5577218 ↗
- Languages:
- English
- ISSNs:
- 1755-5914
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3051.520500
British Library HMNTS - ELD Digital store - Ingest File:
- 17588.xml